BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...
Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...
Background: Among patients with major depressive disorder (MDD), those with treatment-resistant depression (TRD) have a higher economic burden. However, healthcare resource utilization (H...
BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...
Introduction:Ibrutinib and acalabrutinib are both Bruton’s tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Since st...
Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics (OA), have the potential to increase medication adherence in adult patients with schizophrenia. This increas...
Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...
BACKGROUND: To understand heterogeneity among the population with major depressive disorder (MDD) and suicidal ideation (SI) or attempt (SA) (MDD+SI/SA), clusters were identified through ...